Skip to content

Using artificial intelligence to study the law of cancer symptoms can help more accurate diagnosis and individualized treatment

Using artificial intelligence to study the law of cancer symptoms can help more accurate diagnosis and individualized treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111873
Enrollment
Unknown
Registered
2025-11-06
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Breast cancer/Ovarian Cancer Observation group:None

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age: 18-75 years old; 2.Patients with breast cancer or epithelial ovarian cancer who have a clear pathological or histological diagnosis; 3.Patients with perioperative breast cancer, postoperative adjuvant chemotherapy, hormone receptor-positive endocrine therapy in stage I-IIIA, and postoperative chemotherapy for ovarian cancer; 4.ECOG-PS: 0-1 point; 5.Have a certain ability to understand and express, voluntarily participate in this study, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those with severe primary diseases of the heart, brain, liver, kidneys, hematopoietic system, etc. 2. Pregnant women, those who are breastfeeding, people with mental and psychological disorders, and those with intellectual and language disorders, as well as other mental disorders (such as obsessive-compulsive disorder, personality disorders, schizophrenia, bipolar disorder, etc.); 3. Those with primary tumors in other parts of the body; 4.3 Participate in other clinical trials within 3 months;

Design outcomes

Primary

MeasureTime frame
Symptom cluster;

Secondary

MeasureTime frame
Evaluation index of tumor curative effect (progressive disease stable disease partial response complete response);Survival evaluation data (Overall Survival Progression-Free Survival Disease-Free Survival etc.);

Countries

China

Contacts

Public ContactWang Yingyi

Peking Union Medical College Hospital

wangyingyi@pumch.cn+86 132 4101 6888

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026